Topical CP-690,550 For Chronic Plaque Psoriasis

Pfizer

Status and phase

Completed

Phase 2

Conditions

Psoriasis

Treatments

Drug: Placebo Vehicle

Drug: CP-690,550

Study type

Interventional

Funder types

Industry

Identifiers

NCT00678561

A3921038

Details and patient eligibility

About

Study will test effectiveness of an experimental drug applied once or twice daily to two psoriasis plaques. Requires 1 clinic visit each week for 5 weeks.

Enrollment

81 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Having chronic plaque psoriasis for at least 6 months
Able to withdraw all prior psoriasis treatments
Must agree to avoid prolonged exposure to the sun and avoid use of tanning booths or other ultraviolet light sources during the study

Exclusion criteria

Evidence of active, latent, or inadequately treated infection with Mycobacterium tuberculosis
Pregnant or lactating women
Unwilling to use appropriate contraceptive methods

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

81 participants in 8 patient groups, including a placebo group

2% CP-690,550 QD

Experimental group

Treatment:

Drug: CP-690,550

0.2% CP-690,550 QD

Experimental group

Treatment:

Drug: CP-690,550

0.02% CP-690,550 QD

Experimental group

Treatment:

Drug: CP-690,550

2% CP-690,550 BID

Experimental group

Treatment:

Drug: CP-690,550

0.2% CP-690,550 BID

Experimental group

Treatment:

Drug: CP-690,550

0.02% CP-690,550 BID

Experimental group

Treatment:

Drug: CP-690,550

Placebo Vehicle QD

Placebo Comparator group

Treatment:

Drug: Placebo Vehicle

Placebo Vehicle BID

Placebo Comparator group

Treatment:

Drug: Placebo Vehicle

Trial contacts and locations

20

Loading...